|Bid||22.29 x 1000|
|Ask||22.30 x 800|
|Day's range||20.81 - 22.42|
|52-week range||18.01 - 53.73|
|Beta (5Y monthly)||1.17|
|PE ratio (TTM)||N/A|
|Earnings date||04 May 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||51.64|
Esperion Therapeutics (NASDAQ: ESPR) widely missed on its first-quarter results. In Q1 Esperion earned $8 million, over four times the $1.8 million of Q1 2020, fueled by $6.4 million in product revenue (royalty revenue came in at roughly $600,000).
Esperion Therapeutics (ESPR) reports dismal first-quarter results as it misses estimates for earnings and sales. Stock down.
With me on today's call are Tim Mayleben, President and Chief Executive Officer; Sheldon Koenig, Chief Operating Officer; and Rick Bartram, Chief Financial Officer. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the business.